Partnerships are integral to Hikma’s strategy. We remain focused on building an increasingly diverse specialty portfolio through acquisition and partnership, including licensing of NDA/ANDA, generic medicines and biosimilars to help put better health within reach, every day across our regions.
Also, we offer contract manufacturing capabilities leveraging the quality, reliability and flexibility of our manufacturing facilities. We operate 32 manufacturing plants across the US, Europe and the MENA region.
|
|
|
Prefilled syringe |
Tablets |
|
IV bags |
Capsules |
|
Lyophilised |
Nasals |
|
Large parenteral |
Oral solutions |
|
Small parenteral |
|
|
Specialised products |
Specialised products |
|
Cytotoxic/high containment |
High containment |
|
Emulsion |
Respiratory |
|
Cephalosporins |
Controlled substances |
|
Controlled substances |
|
Injectables 
Generics
For all business development enquiries contact:
US and Canada: usbusinessdevelopment@hikma.com
Europe: EUBusinessDevelopment@Hikma.com
MENA:
Adalvo
Allergic Rhinitis (AR)
AFT Pharmaceuticals
Intravenous
Almirall
Dermatology
Astellas
Anti-Infectives and Immunosuppressants
Basilea Pharmaceutica
Anti-infectives
Bio-Thera Solutions, Ltd.
Monoclonal Antibody
BioSapien Inc
Innovative Therapies
Boehringer Ingelheim
Respiratory Diseases
Celltrion
Biological, Oncology and Rheumatology
Eisai
Central Nervous System
FAES Farma
Allergic Rhinitis and Urticaria
Gedeon Richter Plc.
Osteoporosis and Fractures
Glenmark
Seasonal allergic rhinitis
Melinta Therapeutics
Anti-infective
Octapharma
Blood Forming and Rare Diseases
Orion Pharma
Respiratory
Perrigo
Consumer Health
ROVI
Blood and Blood Forming and Cardiovascular
Sesen Bio
Fusion Protein Therapeutics
Tact.ai
Customer Engagement
Takeda
Cardiovascular, Gastrointestinal and Musco-Skeletal
Vifor Pharma
Blood and Blood-Forming and Anti-Anemic
Junshi Biosciences
Latest news
Last reviewed on 30 May 2022